Open Access<p>Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis</p>
Author(s) -
Xin Zhang,
Hejing Huang,
Ziran Wei,
Zhenxin Zhu,
Dejun Yang,
Hongbing Fu,
Jiapeng Xu,
Zunqi Hu,
Yu Zhang,
Qian You,
Xin Huang,
Ran Yan,
Weimin Wang,
Qing-Qing Cai
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s258360
Subject(s) - docetaxel , oxaliplatin , medicine , regimen , oncology , propensity score matching , chemotherapy , leukopenia , stage (stratigraphy) , cancer , univariate analysis , multivariate analysis , colorectal cancer , paleontology , biology
What is the optimal neoadjuvant chemotherapy (NAC) regimen for locally advanced gastric cancer (LAGC) remains debatable. The objective of this study was to compare the efficacy of docetaxel+oxaliplatin+S-1 (DOS) vs oxaliplatin+S-1 (SOX) as NAC for LAGC.